If the tumor is fully eradicated, natural CAR-MAC decay may be adequate, similar to what is observed in CD19 B-cell lymphomas.102–104 Further research is essential to gain deeper insights into CAR-MAC persistence and optimize strategies for maintaining their antitumor activity over time. The gene discussed is CD19; the disease is B-cell non-Hodgkin lymphoma.